• Vaccine Name: HIV DNA vaccine SIVmac239 Gag-Pol-Nef and mock Env with rAd5 boost
• Target Pathogen: Human Immunodeficiency Virus
• Target Disease: Acquired Immunodeficiency Syndrome (AIDS)
• Vaccine Ontology ID: VO_0004349
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Macaque
• Gag protein from SIV-mnd 2 gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• Pol SIV gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• Nef SIV gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• env gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid:
  • DNA vaccine plasmid name:
  • DNA vaccine plasmid VO ID: VO_0000334
• Immunization Route: Intramuscular injection (i.m.)

Macaque Response

• Vaccine Immune Response Type: VO_0000286
• Immune Response: DNA priming-rAd5 boosting immunization platform can elicit potent anti-HIV-1 cellular immune responses and anti-HIV-1 neutralizing antibodies (Mascola et al., 2005).
• Efficacy: In a challenge study, all monkeys were immunized with DNA plasmids at 0, 4, and 8 weeks and boosted with rAd5 at week 26. Serial plasma dilutions were tested against four of the more neutralization-sensitive viruses, and the plasma dilution that produced 50% virus neutralization, which is required to protect 50% of the cells from virus-induced killing, was determined. The data clearly demonstrates that both the vaccine platform and these immunogens elicit IgG-mediated virus neutralization (Mascola et al., 2005).